Contact:
Mento A."Chuck" Soponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018
                                                         FOR IMMEDIATE RELEASE


       ORAGENICS, INC. BEGINS TRADING ON THE OTC BULLETIN BOARD REGISTRY.

ALACHUA, FL (JANUARY 22, 2004) - Oragenics, Inc. (TSX-V:ORA.U),  a publicly held
biotechnology company, today announced that its common shares have been accepted
for quotation on the OTC Bulletin Board, effective immediately. Oragenics' stock
symbol is "OGEN."

Mento "Chuck" Soponis,  president and chief executive officer of Oragenics said,
"This  listing  is  an  important   corporate   milestone  for  Oragenics.   Our
shareholders  should benefit from this event through more efficient trading and,
potentially, increased liquidity in Oragenics' stock."

Oragenics,  Inc. is an emerging  biotechnology  research and development company
that began operations in 1999. Located in Alachua,  Florida at the University of
Florida's  Sid  Martin  Biotechnology   Development   Incubator,   Oragenics  is
developing three new healthcare  products.  The most advanced product is an oral
rinse for the prevention of tooth decay,  which is anticipated to enter clinical
trials  in  2004.   The  second  product  in   pre-clinical   development  is  a
broad-spectrum  antibiotic.  Oragenics is also developing a probiotic product to
maintain oral health.  For more information about Oragenics,  please consult the
Company's website at www.oragenics.com.

SAFE HARBOR  STATEMENT  UNDER THE PRIVATE  SECURITIES  LITIGATION  REFORM ACT OF
1995: This release includes forward-looking  statements which reflect Oragenics'
current  views with respect to future events and  financial  performance.  These
forward-looking statements are based on management's beliefs and assumptions and
information currently available.  The words "believe",  "expect",  "anticipate",
"intend",  "estimate",  "project"  and similar  expressions  which do not relate
solely to historical  matters  identify  forward-looking  statements.  Investors
should be cautious in relying on  forward-looking  statements  because  they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual  results  to  differ   materially   from  those  expressed  in  any  such
forward-looking  statements.  These factors include,  but are not limited to (1)
the  ability to  successfully  complete  development  and  commercialization  of
Oragenics'  Replacement Therapy for prevention of tooth decay, novel antibiotic,
and  probiotic  product for oral health;  (2) the ability to obtain  substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;  and (4) other  factors  detailed from time to time in filings with
the Securities and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking statements.

                                      # # #

         12085 Research Drive o Alachua, FL 32615 o tel: 386.418.4018
                  o fax: 386.462.0875 o oragen@biotech.ufl.org